WallStSmart

Fresenius Medical Care Corporation (FMS)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 2194% more annual revenue ($19.43B vs $846.72M). NUTX leads profitability with a 21.2% profit margin vs 4.8%. NUTX trades at a lower P/E of 7.5x. NUTX earns a higher WallStSmart Score of 63/100 (C+).

FMS

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96

NUTX

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 9.5Value: 8.3Quality: 7.5
Piotroski: 4/9Altman Z: 2.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+68.6%)

Margin of Safety

+68.6%

Fair Value

$76.58

Current Price

$22.35

$54.23 discount

UndervaluedFair: $76.58Overvalued
NUTXUndervalued (+61.7%)

Margin of Safety

+61.7%

Fair Value

$269.07

Current Price

$200.24

$68.83 discount

UndervaluedFair: $269.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.7x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.738/10

Growing faster than its price suggests

NUTX5 strengths · Avg: 9.6/10
P/E RatioValuation
7.5x10/10

Attractively priced relative to earnings

Operating MarginProfitability
57.8%10/10

Strong operational efficiency at 57.8%

EPS GrowthGrowth
95.9%10/10

Earnings expanding 95.9% YoY

Return on EquityProfitability
27.8%9/10

Every $100 of equity generates 28 in profit

Profit MarginProfitability
21.2%9/10

Keeps 21 of every $100 in revenue as profit

Areas to Watch

FMS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

NUTX2 concerns · Avg: 2.5/10
Market CapQuality
$1.32B3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-13.6%2/10

Revenue declined 13.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth. Profitability is solid with margins at 21.2% and operating margin at 57.8%.

Bear Case : FMS

The primary concerns for FMS are Revenue Growth, Altman Z-Score, Return on Equity. Thin 4.8% margins leave little buffer for downturns.

Bear Case : NUTX

The primary concerns for NUTX are Market Cap, Revenue Growth.

Key Dynamics to Monitor

FMS profiles as a value stock while NUTX is a declining play — different risk/reward profiles.

NUTX carries more volatility with a beta of 2.02 — expect wider price swings.

FMS is growing revenue faster at 1.4% — sustainability is the question.

FMS generates stronger free cash flow (620M), providing more financial flexibility.

Bottom Line

NUTX scores higher overall (63/100 vs 58/100), backed by strong 21.2% margins. FMS offers better value entry with a 68.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?